bluebird bio, Inc. (BLUE)
NASDAQ: BLUE · Real-Time Price · USD
4.090
-0.250 (-5.76%)
Apr 23, 2025, 4:00 PM EDT - Market closed
bluebird bio Employees
bluebird bio had 248 employees as of December 31, 2024. The number of employees decreased by 127 or -33.87% compared to the previous year.
Employees
248
Change (1Y)
-127
Growth (1Y)
-33.87%
Revenue / Employee
$337,931
Profits / Employee
-$970,625
Market Cap
40.04M
Employees Chart
Employees History
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novartis AG | 75,883 |
BLUE News
- 8 days ago - bluebird bio confirms that Ayrmid, Ltd. has not delivered a binding offer or obtained necessary financing despite extensive engagement - Business Wire
- 23 days ago - Gene Therapy-Focused Bluebird Bio Receives Rival Takeover Offer, Stock Jumps - Benzinga
- 26 days ago - Bluebird bio receives non-binding bid for up to $110.5 million - Reuters
- 26 days ago - Bluebird Bio Reviewing Buyout Offer From Ayrmid for Up to $110.5 Million -- Update - Market Watch
- 26 days ago - bluebird bio Confirms Receipt of an Unsolicited Non-Binding Proposal from Ayrmid - Business Wire
- 5 weeks ago - BLUEBIRD BIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of bluebird bio, Inc. - BLUE - Business Wire
- 2 months ago - ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of bluebird bio, Inc. - PRNewsWire
- 2 months ago - Once high-flying Bluebird Bio sells itself to private equity after tough times for the gene therapy maker - CNBC